



Tessa Forbes
CoA Therapeutics
421 Kipling Street
Palo Alto, CA 94301

Jill Chertow
President
Propionic Acidemia Foundation
1963 McCraren Road
Highland Park, IL 60035

A message to the PA and MMA community from CoA Therapeutics

At CoA Therapeutics, Inc., an affiliate of BridgeBio Pharma, Inc., we are as committed as ever to moving our program forward to develop our small molecule therapy for patients living with PA and MMA, and other conditions associated with coenzyme A (CoA) deficiency*. We are excited to update you on our recent progress.

We have completed the necessary preclinical studies in animals with our small molecule drug candidate, BBP-671, to support beginning human trials. Additionally, the U.S. Federal Drug Association (FDA) has approved our Investigational New Drug (IND) application to study BBP-671 in humans. In April 2021, we started a Phase 1 study to assess the safety of the drug in healthy volunteers before it is studied in PA and MMA patients. We plan to begin PA and MMA patient trials once we know that the drug candidate is safe, and we have identified a dose appropriate for PA and MMA patients.

We are committed to studying our drug in PA and MMA patients globally. We have been granted Orphan Drug and Rare Pediatric Disease Designations in the United States and we have filed for orphan drug designation in the European Union.

If you would like further information or have any questions, please do not hesitate to contact us at info@coatherapeutics.com.

We know that this continues to be a difficult time for many families, and that current circumstances often pose increased challenges on families caring for patients with PA and MMA. We are committed to advancing our potential therapy for PA and MMA patients as quickly and as safely as possible.

Warm regards,
The CoA Therapeutics Team

**CoA Therapeutics is also developing BBP-671 for the treatment of pantothenate kinase-associated neurodegeneration.*